4512
WAKAMOTO PHARMACEUTICAL CO.,LTD.
わかもと製薬
- Industry
- Pharmaceutical
- Market
- Standard
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(thousand JPY)
Mar 2021
8,895,838
Mar 2022
8,383,145
Mar 2023
8,660,379
Mar 2024
7,738,426
Mar 2025
7,789,462
Operating profit(thousand JPY)
Mar 2021
-754,947
Mar 2022
-13,386
Mar 2023
141,467
Mar 2024
-195,511
Mar 2025
-457,796
Operating profit margin(%)
Mar 2021
-8.49
Mar 2022
-0.16
Mar 2023
1.63
Mar 2024
-2.53
Mar 2025
-5.88
Profit before tax(thousand JPY)
Mar 2021
-703,007
Mar 2022
284,858
Mar 2023
211,574
Mar 2024
158,854
Mar 2025
7,456
Profit(thousand JPY)
Mar 2021
-601,856
Mar 2022
238,543
Mar 2023
138,256
Mar 2024
108,959
Mar 2025
64,440
Total assets(thousand JPY)
Mar 2021
14,572,472
Mar 2022
14,953,435
Mar 2023
15,711,553
Mar 2024
15,421,054
Mar 2025
15,002,709
Cash and cash equivalents(thousand JPY)
Mar 2021
2,843,762
Mar 2022
3,231,889
Mar 2023
3,879,325
Mar 2024
3,664,647
Mar 2025
2,954,759
Cash flows from operating activities(thousand JPY)
Mar 2021
163,438
Mar 2022
339,174
Mar 2023
631,920
Mar 2024
-107,338
Mar 2025
-592,454
Cash flows from investing activities(thousand JPY)
Mar 2021
-199,513
Mar 2022
50,572
Mar 2023
17,131
Mar 2024
-2,352
Mar 2025
-13,498
Cash flows from financing activities(thousand JPY)
Mar 2021
-3,829
Mar 2022
-1,620
Mar 2023
-1,615
Mar 2024
-104,986
Mar 2025
-103,935
Return on equity(%)
Mar 2021
-5.16
Mar 2022
2.09
Mar 2023
1.18
Mar 2024
0.91
Mar 2025
0.55
Equity ratio(%)
Mar 2021
78.13
Mar 2022
76.77
Mar 2023
75.78
Mar 2024
77.98
Mar 2025
77.39
Earnings per share(JPY per share)
Mar 2021
-17.34
Mar 2022
6.87
Mar 2023
3.98
Mar 2024
3.13
Mar 2025
1.85
Net assets per share(JPY per share)
Mar 2021
328.04
Mar 2022
330.79
Mar 2023
343.06
Mar 2024
346.5
Mar 2025
334.53
Dividend per share(JPY per share)
Mar 2021
0
Mar 2022
0
Mar 2023
3
Mar 2024
3
Mar 2025
3
Payout ratio(%)
Mar 2021
-
Mar 2022
0
Mar 2023
75.38
Mar 2024
95.85
Mar 2025
162.16
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.